Vitae Pharma Spikes 158% Following Allergan Buyout

Allergan plc AGN and Vitae Pharmaceuticals Inc VTAE reached an agreement by which the former would buy the latter for $21.00 a share in cash. This would translate into a total transaction value of about $639 million. The companies expect the transaction to be completed before the current year ends.

According to the agreement terms, Allergan's subsidiary would initiate a cash tender offer to buy Vitae shares. The deal enables the company to buy shares that are not tendered in the tender offer through a second-step merger.

Allergan believes the acquisition would strengthen its dermatology product pipeline as Vitae is engaged in a phase 2 study of VTP-43742. Incidentally, the compound completed a second stage proof-of-concept multiple ascending dose trial only recently.

Allergan's CEO and President, Brent Saunders, said, "The acquisition of Vitae is a strategic investment for Allergan that adds strength and depth to our innovative medical dermatology franchise. Vitae has pioneered the discovery and development of highly differentiated first-in-class compounds in atopic dermatitis, psoriasis and autoimmune diseases, areas of medicine where innovation is needed for patients."

After being halted, shares of Vitae traded up more than 155 percent at $12.77 in the pre-market session.

Posted In: BiotechNewsM&AMoversGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.